Skip to main
MDT
MDT logo

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 41 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 39%
Sell 0%
Strong Sell 2%

Bulls say

Medtronic's stock outlook is bolstered by the continued growth in its neuromodulation market share, with the company gaining 240 basis points and demonstrating mid-single-digit revenue growth driven by the adoption of its MiniMed 780G AID system. The company anticipates FY25 revenue growth of 3.4-3.8%, alongside a notable EPS guidance of $5.44-5.50, representing a year-over-year increase of 10-11% excluding foreign exchange impacts. Additionally, Medtronic's non-GAAP gross margin rose by 50 basis points year-over-year, combined with a significant 100 basis point improvement in its non-GAAP operating margin, indicating solid operational performance amid favorable currency effects.

Bears say

Medtronic is facing significant headwinds, with revenue growth projected to slow to low-single digits due to ineffective new product launches and erosion of market share in key categories, contributing to below-consensus earnings expectations. The company's operating margin is anticipated to remain flat or decline, exacerbated by various risks including increased competition, disappointing sales from new offerings, and unfavorable foreign exchange impacts that could further strain profitability. Additionally, research and development expenses have decreased slightly, while selling, general, and administrative costs have risen, indicating potential inefficiencies in cost management amid these financial pressures.

Medtronic (MDT) has been analyzed by 41 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 39% suggest Holding, 0% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 41 analysts, Medtronic (MDT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.